Skip to main navigation Skip to search Skip to main content

Down syndrome and Alzheimer's disease: Common pathways, common goals

  • Dean Hartley
  • , Thomas Blumenthal
  • , Maria Carrillo
  • , Gilbert DiPaolo
  • , Lucille Esralew
  • , Katheleen Gardiner
  • , Ann Charlotte Granholm
  • , Khalid Iqbal
  • , Michael Krams
  • , Cynthia Lemere
  • , Ira Lott
  • , William Mobley
  • , Seth Ness
  • , Ralph Nixon
  • , Huntington Potter
  • , Roger Reeves
  • , Marwan Sabbagh
  • , Wayne Silverman
  • , Benjamin Tycko
  • , Michelle Whitten
  • Thomas Wisniewski
  • National Alzheimer's Association
  • University of Colorado Anschutz Medical Campus
  • Columbia University
  • Trinitas Regional Medical Center
  • Medical University of South Carolina
  • New York State Office for People with Developmental Disabilities
  • Johnson & Johnson
  • Massachusetts General Hospital
  • University of California at Irvine
  • University of California at San Diego
  • New York University
  • University of Colorado Denver
  • Johns Hopkins University
  • Banner Health
  • Kennedy Krieger Institute
  • Global Down Syndrome Foundation

Research output: Contribution to journal › Article › peer-review

248 Scopus citations

Abstract

In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70% will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. Pathogenic and mechanistic links between DS and Alzheimer's prompted the Alzheimer's Association to partner with the Linda Crnic Institute for Down Syndrome and the Global Down Syndrome Foundation at a workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field. The workshop articulated a set of research priorities: (1) target identification and drug development, (2) clinical and pathological staging, (3) cognitive assessment and clinical trials, and (4) partnerships and collaborations with the ultimate goal to deliver effective disease-modifying treatments.

Original languageEnglish
Pages (from-to)700-709
Number of pages10
JournalAlzheimer's and Dementia
Volume11
Issue number6
DOIs
StatePublished - 1 Jun 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • ADNI
  • Alzheimer's disease
  • Amyloid precursor protein
  • Animal models
  • Beta-amyloid
  • Biomarkers
  • Clinical trials
  • Cognitive assessment
  • DS-Connect
  • Dementia
  • Down syndrome
  • Drug discovery
  • Neuroimaging
  • Neuroinflammation
  • Tau
  • Trisomy 21
  • Ts65Dn
  • Workshop

Fingerprint

Dive into the research topics of 'Down syndrome and Alzheimer's disease: Common pathways, common goals'. Together they form a unique fingerprint.

Cite this